Agios Pharmaceuticals, INC

Agios Pharmaceuticals reported strong second quarter 2026 results, with mitapivat revenues reaching $44.7 million and significant pipeline advancements.

Agios Pharmaceuticals stockholders approved an amendment to the 2023 Stock Incentive Plan, increasing available shares and authorizing incentive stock options.

Agios Pharmaceuticals announced first quarter 2026 financial results, highlighting strong net revenue growth for mitapivat and progress in its drug pipeline.

Agios Pharmaceuticals announced strong fourth-quarter and full-year 2025 financial results, highlighted by the U.S. launch of AQVESME and progress in its sickle cell disease programs.

Agios Pharmaceuticals announced its 2026 strategic priorities and key milestones, including the U.S. commercial launch of AQVESME for thalassemia and pipeline advancements.

Agios Pharmaceuticals announced its third quarter 2025 financial results, reporting $12.9 million in PYRUKYND net revenues and providing updates on key clinical and regulatory milestones for its rare disease pipeline.

Agios Pharmaceuticals reports increased product revenue driven by AQVESME sales, alongside significant R&D investments and a net loss for the quarter.

Agios Pharmaceuticals reported a significant increase in product revenue for Q1 2026, driven by AQVESME and PYRUKYND sales, though net loss also widened due to increased R&D and SG&A expenses.

Agios Pharmaceuticals reports increased PYRUKYND product revenue in Q3 2025, but faces a three-month FDA review extension for PYRUKYND in thalassemia due to a REMS submission.

Agios Pharmaceuticals reported a wider net loss in the second quarter of 2025 due to increased research and development and commercialization expenses, despite a rise in PYRUKYND product revenue, as the company advances its rare disease pipeline.

Agios Pharmaceuticals announces its Q1 2025 financial results, showcasing progress with PYRUKYND and its pipeline.

Agios Pharmaceuticals reports a significant net income for the third quarter of 2024, primarily driven by the sale of Vorasidenib royalty rights and a milestone payment.

Agios Pharmaceuticals received FDA approval for AQVESME in thalassemia and a positive EU opinion for PYRUKYND in thalassemia, while reporting a return to net loss and mixed results from its sickle cell disease trial.

Agios Pharmaceuticals achieved net income in 2024 due to the sale of oncology royalty rights and a milestone payment, while advancing its rare disease pipeline, particularly PYRUKYND.

Agios Pharmaceuticals reports its full year 2023 financial results, highlighting progress in its rare disease pipeline and commercialization of PYRUKYND.

Jay Backstrom, a Director at Agios Pharmaceuticals, Inc., reported a transaction involving restricted stock units and common stock.

AGIOS PHARMACEUTICALS, INC. reports a transaction where Chief Medical Officer Sarah Gheuens sold shares to cover tax obligations related to restricted stock units.

Agios Pharmaceuticals Director Catherine Owen acquired 1,976 restricted stock units on June 13, 2026, as part of a vesting schedule.

Agios Pharmaceuticals Director Jeffrey D. Capello acquired 1,976 shares of common stock through restricted stock units, increasing his beneficial ownership.

Agios Pharmaceuticals Chief Legal Officer James William Burns reported a transaction involving the sale of common stock to cover tax withholding obligations related to vested performance share units.

AGIOS PHARMACEUTICALS, INC. reports a Form 4 filing detailing a transaction by Chief Medical Officer Sarah Gheuens, involving the sale of shares to cover tax obligations following the achievement of a regulatory milestone.

Agios Pharmaceuticals seeks stockholder approval for director elections, executive compensation, and a 2,000,000 share increase to its 2023 Stock Incentive Plan.

Agios Pharmaceuticals will hold its annual stockholders meeting on June 18, 2025, to vote on director elections, executive compensation, a stock incentive plan amendment, and the ratification of its accounting firm.

Agios Pharmaceuticals is asking stockholders to approve an amendment to its 2023 Stock Incentive Plan to increase the number of shares available for issuance by 2,500,000.

Agios Pharmaceuticals will hold its annual stockholders meeting on June 20, 2024, to elect directors, approve executive compensation, and ratify the appointment of its accounting firm.

Agios Pharmaceuticals will hold its annual stockholders meeting virtually on June 20, 2024, to vote on director elections, executive compensation, and auditor ratification.

Farallon Capital Management, L.L.C. and its affiliates have reported beneficial ownership of 5,917,400 shares, representing 9.9% of the outstanding common stock of Agios Pharmaceuticals, Inc.

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 4.57% of Agios Pharmaceuticals, Inc. common stock as of March 31, 2026.

Lynx1 Capital Management LP and Weston Nichols have jointly filed a Schedule 13G, reporting beneficial ownership of 5.1% of Agios Pharmaceuticals, Inc. common stock.

The Vanguard Group has amended its Schedule 13G, reporting 0% beneficial ownership in Agios Pharmaceuticals Inc due to an internal realignment.

Farallon Capital Management and its affiliates updated their beneficial ownership in Agios Pharmaceuticals, Inc. to 8.8%, reflecting internal management changes within Farallon.

State Street Corporation has reported a 5.3% beneficial ownership stake in Agios Pharmaceuticals Inc., holding 3,108,145 common shares as of December 31, 2025.